Modality
siRNA
MOA
CGRPant
Target
TROP-2
Pathway
STING
Hemophilia A
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
Jul 2020
→ Mar 2028
Phase 2Current
NCT05496148
270 pts·Hemophilia A
2020-07→2028-03·Recruiting
270 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-262.0y awayPh2 Data· Hemophilia A
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Recruit…
Catalysts
Ph2 Data
2028-03-26 · 2.0y away
Hemophilia A
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05496148 | Phase 2 | Hemophilia A | Recruiting | 270 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |